Biodesix to sell $55M in stock
LOUISVILLE — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, expects to raise about $55 million through stock sales.
The company plans a public offering of nearly 17.4 million common shares and a private sale of 760,857 shares of preferred stock.
“Certain members of management, certain of our directors and funds affiliated with these directors are participating in the concurrent private placement,” Biodesix said in a regulatory disclosure.
SPONSORED CONTENT
TD Cowen, William Blair and Canaccord Genuity are acting as joint bookrunning managers for the stock sales.